First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. [electronic resource]
Producer: 20150728Description: 5908-17 p. digitalISSN:- 1557-3265
- Administration, Oral
- Adult
- Aged
- Antineoplastic Agents -- pharmacology
- Class I Phosphatidylinositol 3-Kinases -- antagonists & inhibitors
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis
- Neoplasms -- diagnosis
- Positron-Emission Tomography
- Pyrimidines -- pharmacology
- Sulfonamides -- pharmacology
- Tomography, X-Ray Computed
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.